Renovorx reports first quarter 2022 financial results

Los altos, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended march 31, 2022. “as we report our q1 2022 results, we acknowledge that may is cancer research month. renovorx is fighting cancer through our innovative localized treatment of difficult-to-treat tumors via our proprietary renovotamp™ (renovorx trans-arterial micro-perfu
RNXT Ratings Summary
RNXT Quant Ranking